N-Acetylcysteine Use to Prevent Contrast Medium-induced Nephropathy: Premature Phase III Trials

Journal of Vascular and Interventional Radiology

Volumn 19, Issue 3, 2008, Pages 309-318

  Stenstrom, David A ^a   Muldoon, Leslie L ^a,b   Armijo Medina, Hector ^a   Watnick, Suzanne ^c   Doolittle, Nancy D ^a   Kaufman, John A ^b   Peterson, Darryl R ^e   Bubalo, Joseph ^b   Neuwelt, Edward A ^a,b,d  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Nephrology Section   (United States)

^d PORTLAND VA MEDICAL CENTER   (United States)

^e ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CISPLATIN;

CLINICAL TRIAL; CONTRAST MEDIUM INDUCED NEPHROPATHY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; KIDNEY DISEASE; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; SINGLE DRUG DOSE;

ACETYLCYSTEINE; CLINICAL TRIALS, PHASE III AS TOPIC; CONTRAST MEDIA; HUMANS; KIDNEY DISEASES;

EID: 39449083331     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2007.11.003     Document Type: Review

References (74)

1. Tepel M., van der Giet M., Schwarzfeld C., Laufer U., Liermann D., and Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343 (2000) 180-184
2. Schultz M.J., Baas M.C., van der Sluijs H.P., Stamkot G.A., and Smit W. N-acetylcysteine and other preventive measures for contrast-induced nephropathy in the intensive care unit. Curr Med Chem 13 (2006) 2565-2570
3. McCullough P.A., Adam A., Becker C.R., et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 98 (2006) 5K-13K
4. Marenzi G., Assanelli E., Marana I., et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354 (2006) 2773-2782
5. Baker C.S., Wragg A., Kumar S., De Palma R., Baker L.R., and Knight C.J. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 41 (2003) 2114-2118
6. Solomon R., and Barrett B. Follow-up of patients with contrast-induced nephropathy. Kidney Int 69 suppl S100 (2006) S46-S50
7. Briguori C., Manganelli F., Scarpato P., et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 40 (2002) 298-303
8. Weisbord S.D., and Palevsky P.M. Radiocontrast-induced acute renal failure. J Intens Care Med 20 (2005) 63-75
9. Diaz-Sandoval L.J., Kosowsky B.D., and Losordo D.W. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 89 (2002) 356-358
10. Tumlin J., Stacul F., Adam A., et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 98 (2006) 14K-20K
11. Aspelin P., Aubry P., Fransson S.G., Strasser R., Willenbrock R., and Berg K.J. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 348 (2003) 491-499
12. Briguori C., Colombo A., Airoldi F., et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 68 (2005) 2250-2255
13. Gulel O., Keles T., Eraslan H., Aydogdu S., Diker E., and Ulusoy V. Prophylactic acetylcysteine usage for prevention of contrast nephropathy after coronary angiography. J Cardiovasc Pharmacol 46 (2005) 464-467
14. Solomon R., Biguori C., and Bettmann M. Selection of contrast media. Kidney Int 69 suppl (2006) S39-S45
15. Vlietstra R.E., Nunn C.M., Narvarte J., and Browne K.F. Contrast nephropathy after coronary angioplasty in chronic renal insufficiency. Am Heart J 132 (1996) 1049-1050
16. Sandhu C., Newman D.J., Morgan R., Belli A.M., and Oliveira D. The role of oxygen free radicals in contrast induced nephrotoxicity. Acad Radiol 9 suppl 2 (2002) S436-S437
17. Mueller C. Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int suppl (2006) S16-S19
18. Molnar Z., MacKinnon K.L., Shearer E., Lowe D., and Watson I.D. The effect of N-acetylcysteine on total serum anti-oxidant potential and urinary albumin excretion in critically ill patients. Intens Care Med 24 (1998) 230-235
19. Borgstrom L., Kagedal B., and Paulsen O. Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 31 (1986) 217-222
20. Bonanomi L., and Gazzaniga A. Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur J Respir Dis Suppl 111 (1980) 45-51
21. Shalansky S.J., Vu T., Pate G.E., Levin A., Humphries K.H., and Webb J.G. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best?. Pharmacotherapy 25 (2005) 1095-1103
22. Skrzydlewska E., and Farbiszewski R. Protective effect of N-acetylcysteine on reduced glutathione, reduced glutathione-related enzymes and lipid peroxidation in methanol intoxication. Drug Alcohol Depend 57 (1999) 61-67
23. Zafarullah M., Li W.Q., Sylvester J., and Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60 (2003) 6-20
24. Dickey D.T., Muldoon L.L., Kraemer D.F., and Neuwelt E.A. Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hearing Res 193 (2004) 25-30
25. Olsson B., Johansson M., Gabrielsson J., and Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 34 (1988) 77-82
26. Tsikas D., Sandmann J., Ikic M., Fauler J., Stichtenoth D.O., and Frolich J.C. Analysis of cysteine and N-acetylcysteine in human plasma by high-performance liquid chromatography at the basal state and after oral administration of N-acetylcysteine. J Chromatogr B Biomed Sci Appl 708 (1998) 55-60
27. Lewis P.A., Woodward A.J., and Maddock J. Improved method for the determination of N-acetylcysteine in human plasma by high-performance liquid chromatography. J Chromatogr 327 (1985) 261-267
28. Burgunder J.M., Varriale A., and Lauterburg B.H. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 36 (1989) 127-131
29. Brown M., Bjorksten A., Medved I., and McKenna M. Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise. Eur J Clin Pharmacol 60 (2004) 717-723
30. Doolittle N., Lacy C., Tyson R., Haluska M., et al. Phase I study of N-acetylcysteine administered in the descending aorta in conjunction with carboplatin-based blood-brain barrier disruption (BBBD) in subjects with malignant brain tumors. Neuro-Oncology 5 (2003) 350
31. Neuwelt E.A., Pagel M.A., Hasler B.P., Deloughery T.G., and Muldoon L.L. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 61 (2001) 7868-7874
32. Dickey D.T., Muldoon L.L., Doolittle N.D., Peterson D.R., and Neuwelt E.A. Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. Cancer Chemother Pharmacol (2007) [Epub ahead of print, Oct]
33. ACETADOTE (acetylcysteine) injection [prescribing information] (2004), Cumberland Pharmaceuticals, Nashville, TN
34. Kao L.W., Kirk M.A., Furbee R.B., Mehta N.H., Skinner J.R., and Brizendine E.J. What is the rate of adverse events after oral N-acetylcysteine administered by the intravenous route to patients with suspected acetaminophen poisoning?. Ann Emerg Med 42 (2003) 741-750
35. Marzullo L. An update of N-acetylcysteine treatment for acute acetaminophen toxicity in children. Curr Opin Pediatr 17 (2005) 239-245
36. Appelboam A.V., Dargan P.I., and Knighton J. Fatal anaphylactoid reaction to N-acetylcysteine: caution in patients with asthma. Emerg Med J 19 (2002) 594-595
37. Vale J.A., and Wheeler D.C. Anaphylactoid reaction to acetylcysteine. Lancet 2 (1982) 988
38. Mant T.G., Tempowski J.H., Volans G.N., and Talbot J.C. Adverse reactions to acetylcysteine and effects of overdose. Br Med J (Clin Res Ed) 289 (1984) 217-219
39. Dawson A.H., Henry D.A., and McEwen J. Adverse reactions to N-acetylcysteine during treatment for paracetamol poisoning. Med J Aust 150 (1989) 329-331
40. Kay J., Chow W.H., Chan T.M., et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 289 (2003) 553-558
41. Gomes V.O., Poli de Figueredo C.E., Caramori P., et al. N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial. Heart 91 (2005) 774-778
42. Coyle L.C., Rodriguez A., Jeschke R.E., Simon-Lee A., Abbott K.C., and Taylor A.J. Acetylcysteine In Diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Am Heart J 151 (2006) 1032 e1039-e1012
43. Carbonell N., Blasco M., Sanjuan R., et al. Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: a randomised trial. Int J Cardiol 115 (2007) 57-62
44. Briguori C., Colombo A., Violante A., et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 25 (2004) 206-211
45. Boccalandro F., Amhad M., Smalling R.W., and Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Cathet Cardiovasc Intervent 58 (2003) 336-341
46. Azmus A.D., Gottschall C., Manica A., et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Invas Cardiol 17 (2005) 80-84
47. Shyu K.G., Cheng J.J., and Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 40 (2002) 1383-1388
48. Webb J.G., Pate G.E., Humphries K.H., et al. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 148 (2004) 422-429
49. Rashid S.T., Salman M., Myint F., et al. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg 40 (2004) 1136-1141
50. Kotlyar E., Keogh A.M., Thavapalachandran S., et al. Prehydration alone is sufficient to prevent contrast-induced nephropathy after day-only angiography procedures-a randomised controlled trial. Heart Lung Circ 14 (2005) 245-251
51. Oldemeyer J.B., Biddle W.P., Wurdeman R.L., Mooss A.N., Cichowski E., and Hilleman D.E. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J 146 (2003) E23
52. Tadros G.M., Mouhayar E.N., Akinwande A.O., Campbell B., Wood C., and Blankenship J.A. Prevention of radiocontrast-induced nephropathy with N-acetylcysteine in patients undergoing coronary angiography. J Invas Cardiol 15 (2003) 311-314
53. MacNeill B.D., Harding S.A., Bazari H., et al. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Cathet Cardiovasc Intervent 60 (2003) 458-461
54. Efrati S., Dishy V., Averbukh M., et al. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int 64 (2003) 2182-2187
55. Ochoa A., Pellizzon G., Addala S., et al. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention. J Interv Cardiol 17 (2004) 159-165
56. Miner S.E., Dzavik V., Nguyen-Ho P., et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 148 (2004) 690-695
57. Drager L.F., Andrade L., Barros de Toledo J.F., Laurindo F.R., Machado Cesar L.A., and Seguro A.C. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant 19 (2004) 1803-1807
58. Allaqaband S., Tumuluri R., Malik A.M., et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Cathet Cardiovasc Intervent 57 (2002) 279-283
59. Durham J.D., Caputo C., Dokko J., et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 62 (2002) 2202-2207
60. Goldenberg I., Shechter M., Matetzky S., et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J 25 (2004) 212-218
61. Kefer J.M., Hanet C.E., Boitte S., Wilmotte L., and De Kock M. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient?. Acta Cardiol 58 (2003) 555-560
62. Fung J.W., Szeto C.C., Chan W.W., et al. Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. Am J Kidney Dis 43 (2004) 801-808
63. Alonso A., Lau J., Jaber B.L., Weintraub A., and Sarnak M.J. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 43 (2004) 1-9
64. Birck R., Krzossok S., Markowetz F., Schnulle P., van der Woude F.J., and Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 362 (2003) 598-603
65. Duong M.H., MacKenzie T.A., and Malenka D.J. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Cathet Cardiovasc Intervent 64 (2005) 471-479
66. Guru V., and Fremes S.E. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol 62 (2004) 77-83
67. Isenbarger D.W., Kent S.M., and O'Malley P.G. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 92 (2003) 1454-1458
68. Liu R., Nair D., Ix J., Moore D.H., and Bent S. N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med 20 (2005) 193-200
69. Misra D., Leibowitz K., Gowda R.M., Shapiro M., and Khan I.A. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol 27 (2004) 607-610
70. Nallamothu B.K., Shojania K.G., Saint S., et al. Is acetylcysteine effective in preventing contrast-related nephropathy?. A meta-analysis. Am J Med 117 (2004) 938-947
71. Pannu N., Manns B., Lee H., and Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 65 (2004) 1366-1374
72. Bagshaw S.M., and Ghali W.A. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med 2 (2004) 38
73. Kshirsagar A.V., Poole C., Mottl A., et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 15 (2004) 761-769
74. Zagler A., Azadpour M., Mercado C., and Hennekens C.H. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 151 (2006) 140-145